$2750 | Single User
$5500 | Site License
$8250 | Enterprise License

Multiple Myeloma -Epidemiology Forecast to 2025
[Report Updated: 10-10-2017]

Published by Delve Insight: 10 Oct 2017 | 139027 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

DelveInsight “Multiple Myeloma - Epidemiology Forecast To 2025” provides an overview of the epidemiology trends of Multiple Myeloma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Multiple Myeloma prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Multiple Myeloma. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Scope of the Report

The Report includes the prevalent population and how will it change over the next eight years.

Prevalent or incident cases segmented by age and sex.

Coverage of key Multiple Myeloma subpopulations and its prevalent or incident cases

The key differences in epidemiology patterns across the seven market segments

Key Coverage and Benefits

The report will help in developing business strategies by understanding the trends shaping and driving the global Multiple Myeloma market.

Identifying prevalent patient populations as well as risk factors in the global Multiple Myeloma market will help to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma therapeutics in each of the markets covered.

Table of Contents
for Multiple Myeloma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

  • 1. Report Introduction

    2. Snapshot of Total Prevalent or Incident cases by 7 MM

    3. Executive Summary

    • Key Findings

    4. Multiple Myeloma Overview

    • Multiple Myeloma Definition

    • Pathophysiology

    • Symptoms

    5. Etiology

    6. Risk Factors Associated with Multiple Myeloma

    7. Disease Burden & Unmet Need in the Market

    8. Epidemiology and Patient Populations

    • Key Findings

    • Key Sources used and Forecast Methodology

    • Prevalent Cases and Incident Cases-2015-2025

    • Prevalent & Incident Cases by Category-2015-2025

    • Age-Specific Prevalent/ Incident Cases of Multiple Myeloma

    • Sex-Specific Prevalent/Incident Cases of Multiple Myeloma

    • Disease Type Specific Prevalent/Incident Cases of Multiple Myeloma

    9. Prevalent & Incident Cases by 7 MM-2015-2025

    • Multiple Myeloma Epidemiology of United States-2025

    • Multiple Myeloma Epidemiology of United Kingdom-2025

    • Multiple Myeloma Epidemiology of Germany-2025

    • Multiple Myeloma Epidemiology of France-2025

    • Multiple Myeloma Epidemiology of Spain-2025

    • Multiple Myeloma Epidemiology of Italy-2025

    • Multiple Myeloma Epidemiology of Japan-2025

    10. Key Takeaways

    11. Appendix

    12. Report Methodology

    13. Consulting Services

List Of Tables
in Multiple Myeloma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

Table 1: Clinical subtypes of Indication

Table 2: Risk Factors

Table 3: Prevalence cases (%) Region wise

Table 4: Sources used for forecasting the data

Table 5: Multiple Myeloma Global Epidemiology, (2015-2025)

Table 6: Prevalent Cases of Multiple Myeloma (Ages =XX Years), US (2015-2025)

Table 7: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), US (2015-2025)

Table 8: Prevalent Cases By Multiple Myeloma Sub-population, US (2015-2025)

Table 9: Prevalent Cases of Multiple Myeloma (Ages =XX Years), United Kingdom (2015-2025)

Table 10: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), United Kingdom (2015-2025)

Table 11: Prevalent Cases By Multiple Myeloma Sub-population, United Kingdom (2015-2025)

Table 12: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Germany (2015-2025)

Table 13: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Germany (2015-2025)

Table 14: Prevalent Cases By Multiple Myeloma Sub-population, Germany (2015-2025)

Table 15: Prevalent Cases of Multiple Myeloma (Ages =XX Years), France (2015-2025)

Table 16: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), France (2015-2025)

Table 17: Prevalent Cases By Multiple Myeloma Sub-population, France (2015-2025)

Table 18: Prevalent Cases of Multiple Myeloma(Ages =XX Years), Italy (2015-2025)

Table 19: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Italy (2015-2025)

Table 20: Prevalent Cases By Multiple Myeloma Sub-population, Italy (2015-2025)

Table 21: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Spain (2015-2025)

Table 22: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Spain (2015-2025)

Table 23: Prevalent Cases By Multiple Myeloma Sub-population, Spain (2015-2025)

Table 24: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Japan (2015-2025)

Table 25: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Japan (2015-2025)

Table 26: Prevalent Cases By Multiple Myeloma Sub-population, Japan (2015-2025)

List Of Figures, Charts and Diagrams
in Multiple Myeloma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]

Figure 1: Prevalence cases (%) Region wise

Figure 2: Sources used for forecasting the data

Figure 3: Multiple Myeloma Global Epidemiology, (2015-2025)

Figure 4: Prevalent Cases of Multiple Myeloma (Ages =XX Years), US (2015-2025)

Figure 5: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), US (2015-2025)

Figure 6: Prevalent Cases By Multiple Myeloma Sub-population, US (2015-2025)

Figure 7: Prevalent Cases of Multiple Myeloma (Ages =XX Years), United Kingdom (2015-2025)

Figure 8: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), United Kingdom (2015-2025)

Figure 9: Prevalent Cases By Multiple Myeloma Sub-population, United Kingdom (2015-2025)

Figure 10: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Germany (2015-2025)

Figure 11: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Germany (2015-2025)

Figure 12: Prevalent Cases By Multiple Myeloma Sub-population, Germany (2015-2025)

Figure 13: Prevalent Cases of Multiple Myeloma (Ages =XX Years), France (2015-2025)

Figure 14: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), France (2015-2025)

Figure 15: Prevalent Cases By Multiple Myeloma Sub-population, France (2015-2025)

Figure 16: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Italy (2015-2025)

Figure 17: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Italy (2015-2025)

Figure 18: Prevalent Cases By Multiple Myeloma Sub-population, Italy (2015-2025)

Figure 19: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Spain (2015-2025)

Figure 20: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Spain (2015-2025)

Figure 21: Prevalent Cases By Multiple Myeloma Sub-population, Spain (2015-2025)

Figure 22: Prevalent Cases of Multiple Myeloma (Ages =XX Years), Japan (2015-2025)

Figure 23: Prevalent Cases of Multiple Myeloma By Sex (Males & Females), Japan (2015-2025)

Figure 24: Prevalent Cases By Multiple Myeloma Sub-population, Japan (2015-2025)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

139027 | DIEI0321

Number of Pages

40

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Multiple Myeloma -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...